Cargando…
Survival improvement with combined radio-chemotherapy in the primary central nervous system lymphomas.
The benefits of radio-chemotherapy in HIV-negative primary central nervous system (CNS) lymphomas were analyzed in 40 patients, who received radiotherapy to the brain or craniospinal axis with the total dose of 4460-5940 cGy to the primary tumor. Radiotherapy was followed by systemic chemotherapy, m...
Autores principales: | Wu, H. G., Kim, I. H., Ha, S. W., Park, C. I., Bang, Y. J., Huh, D. S. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Korean Academy of Medical Sciences
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3054450/ https://www.ncbi.nlm.nih.gov/pubmed/10576154 |
Ejemplares similares
-
TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy
por: Munch-Petersen, Helga D., et al.
Publicado: (2016) -
Primary central nervous system lymphoma
por: Löw, Sarah, et al.
Publicado: (2018) -
A Case of the Cauda Equina Syndrome Associated With the Intrathecal Chemotherapy in a Patient With Primary Central Nervous System Lymphoma
por: Park, Seunglee, et al.
Publicado: (2013) -
Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
por: Sun, Xuefei, et al.
Publicado: (2017) -
Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas
por: Kim, Young-Joo, et al.
Publicado: (2015)